New England Journal of Medicine publishes two related reports evaluating mavacamten, a cardiac myosin inhibitor, in people with hypertrophic cardiomyopathy. One report focuses on adolescents with obstructive hypertrophic cardiomyopathy and describes the clinical findings from an “ahead of print” publication. A second NEJM item discusses mavacamten in nonobstructive hypertrophic cardiomyopathy, appearing in the journal’s June 18, 2026 issue (Volume 394, Issue 23). Together, the two publications address whether mavacamten’s effects extend beyond the obstructive form of the disease and whether similar treatment approaches are studied in younger patients. The NEJM items are presented as primary research communications within the journal, reflecting ongoing efforts to characterize benefits and clinical performance of mavacamten across different disease presentations. Both reports are framed within the broader context of hypertrophic cardiomyopathy care and aim to inform clinical understanding for obstructive and nonobstructive variants, including in adolescent patients with obstructive disease.